Expansion

argenx to buy California biotech Unnatural Products for up to $1.15bn

The Netherlands-based immunology company plans to retain Unnatural Products’ Santa Cruz team as a peptide-discovery hub, extending its research beyond antibodies.

Scaling in America Editorial10 Nov 2026
Netherlands→Santa Cruz, CA
Company: argenx
Illustration for: Argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
Illustration for: Argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

Netherlands-based argenx has agreed to acquire California biotechnology company Unnatural Products in a transaction worth up to approximately $1.15 billion, adding a US discovery platform intended to broaden its immunology research beyond antibody-based medicines.

The agreement includes $550 million in upfront cash and up to $595 million in payments tied to development and regulatory milestones. Both boards have approved the transaction, which is expected to close by the end of 2026, subject to customary closing conditions. According to Grafa’s account of the deal, argenx will fund the acquisition with cash on hand.

Unnatural Products, known as UNP, will remain in Santa Cruz after completion, becoming argenx’s dedicated macrocyclic peptide-discovery hub. Its existing team and leadership will lead discovery activities under an agreed framework, while argenx will oversee clinical development and commercialization.

From research partner to US discovery hub

The acquisition builds on more than two years of multi-target research collaboration and an existing minority investment by argenx. It therefore represents a move from partnership to ownership of a US research operation, rather than a first entry into the American healthcare market.

UNP employs more than 50 people, according to its announcement. Retaining that team and its California location puts continuity at the centre of the integration plan: argenx is acquiring an established discovery operation rather than announcing a new laboratory to be built from scratch.

Founded in 2016 by Cameron Pye and Joshua Schwochert during the final year of their doctoral research at the University of California, Santa Cruz, UNP combines AI-guided design, massively parallel synthesis and direct-to-biology screening. Its platform is designed to engineer drug-like macrocycles at scale.

The company also lists partnerships with Novartis, Merck and BridgeBio alongside its collaboration with argenx. Those relationships provide context for the platform’s pharmaceutical-industry reach; the acquisition announcement does not detail how they will be handled after closing.

Broadening the toolkit beyond antibodies

Macrocyclic peptides are ring-shaped molecules. UNP’s work focuses on developing orally delivered medicines against targets that have traditionally been difficult to address with drugs, including targets inside cells. The strategic aim is to combine those capabilities with argenx’s antibody engineering, creating additional ways to pursue treatments for autoimmune diseases and other serious conditions.

“UNP adds macrocyclic peptide capabilities that are highly complementary to our antibody engineering and creates new possibilities for oral and long-acting medicines,” argenx chief executive Karen Massey said in UNP’s announcement.

Those possibilities remain development ambitions, not approved products. The transaction’s structure also distinguishes the upfront purchase price from its headline value: $595 million of potential consideration depends on future development and regulatory milestones. For argenx, the immediate addition is a discovery capability and specialist team, with clinical development and commercialization to follow for any resulting medicines.

Alongside an existing US regulatory push

The deal comes as argenx seeks to expand the uses of its existing immunology medicines in the United States. On November 7, the company reported that its Phase 3 ALKIVIA study of efgartigimod in autoimmune myositis met its primary and key secondary endpoints in the combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis.

argenx said it plans to submit a supplemental application to the US Food and Drug Administration for efgartigimod in IMNM by the end of 2026. Together, the planned filing and acquisition illustrate two distinct priorities: extending the reach of an existing medicine while investing in a California research platform that could supply a broader future pipeline.

argenxUnnatural ProductsBiotechnologyImmunologyPeptide discoverySanta CruzCross-border acquisition

Related Stories

Keep reading
Illustration for: Argenx agrees to acquire Unnatural Products for up to $1.15 billion
Illustration for: Sports Memorabilia Seller MWS Raises $20 Million To Accelerate U.S. Expansion
Illustration for: Incision secures €4 million to help operating room and sterile processing teams prepare for every procedure